secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2022-03-14T23:59:59+00:00
Accession:  0001564590-22-010094
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARCA biopharma reports FY2021 net loss $19.3M, cash $53.4M; rNAPc2 data due late March 2022
--------------------------------------------------------------------------------

- Net loss $19.3M ($1.39/share) vs $9.7M ($2.07/share) in FY2020; total operating expenses $19.3M.
- Cash and equivalents $53.4M at Dec 31, 2021, up from $49.1M; runway through mid-2023.
- R&D expenses $13.8M (up from $5.0M) driven by rNAPc2 trial; FY2022 R&D expected similar.
- Topline data from Phase 2b ASPEN-COVID-19 trial for rNAPc2 anticipated last week of March 2022.
- Gencaro paper published in Heart Rhythm O2; company evaluating PRECISION-AF trial feasibility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000156459022010094/0001564590-22-010094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000156459022010094/abio-8k_20220314.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-010094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer